CARISMA Therapeutics Inks $59M Series B

USA –

PHILADELPHIA, PA, CARISMA Therapeutics added $12M to its Series B.
CARISMA Therapeutics, a biopharmaceutical company, announced the second closing of its Series B equity financing, bringing the total amount raised in this round to $59 million and CARISMA's total capital raised to date to nearly $121 million.

The second closing of the Series B round included additional funding from founding investors, IP Group, Inc. and Penn Medicine, and new investor 4BIO Capital. They join the initial Series B investor syndicate of SymBiosis II, Solasta Ventures, Livzon Pharmaceuticals Group, AbbVie Ventures, HealthCap, Wellington Partners, TPG Biotech, Agent Capital and MRL Ventures Fund.

Carisma Therapeutics

3025 Market Street, Ste. 140 – Philadelphia, PA 19104

484-899-0326

http://carismatx.com/